Challenging Half for Biotech Sector Following Major US Trade and FDA Changes and Uncertainties Ahead

Is a Biotech Sector Resurgence Underway?

A Record $1.2 Billion Raised in First Half 2024

Volatile Half for Australian Biotech Sector

Capital Starts Return to Biotech Sector

Australian Biotechs Expected to Continue Recovery into 2023

Worst Biotech Half on Record – Sector Down 41%

Australian Biotech's on Acquisition Path

Australian Biotech Attracts $1.9 Billion in Capital

Biotech Stock Demand Settles in June Quart